

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for any securities. Potential investors should read the Prospectus for detailed information about the Company and the Global Offering before deciding whether or not to invest in the Offer Shares.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States or any other jurisdiction where such distribution is prohibited by law. This announcement does not constitute and is not an offer to sell or a solicitation of any offer to buy securities in Hong Kong, the United States or elsewhere. The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act or any state securities laws of the United States and may not be offered or sold in the United States absent registration under the U.S. Securities Act or except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act. There will be no public offering of securities of the Company in the United States, the State of Israel or any jurisdiction other than Hong Kong.

Sisram Medical Ltd

(Incorporated in Israel with limited liability)

Stock code: 1696

MIXED MEDIA OFFER

The Company will be issuing the Prospectus on Tuesday, September 5, 2017 in connection with the proposed Global Offering. An application has been made by the Company to the Listing Committee of the Stock Exchange for the granting of the approval for the listing of, and permission to deal in, the Shares in issue and to be issued pursuant to the Capitalization Issue and the Global Offering. Dealings in the Shares on the Stock Exchange are expected to commence at 9:00 a.m. on Tuesday, September 19, 2017.

The Company will be relying on Section 9A of the Companies (Exemption of Companies and Prospectuses from Compliance with Provisions) Notice (Chapter 32L of the Laws of Hong Kong) and will be issuing (a) the **WHITE** and **YELLOW** Application Forms without them being accompanied by a printed Prospectus and (b) the **BLUE** Application Forms to the relevant Qualifying Fosun International Shareholders without them being accompanied by a printed Prospectus, unless the relevant Qualifying Fosun International Shareholders have elected to receive corporate communications in printed form under Fosun International's corporate communications policy or have not been asked to elect the means of receiving Fosun

International’s corporate communications, in which case the printed Prospectus will be despatched to them separately. The contents of the printed Prospectus are identical to the electronic version of the Prospectus which can be accessed and downloaded from the websites of the Company at www.sisram-medical.com and the Stock Exchange at www.hkexnews.hk under the “*HKExnews > Listed Company Information > Latest Listed Company Information*” section, respectively.

Members of the public may obtain a copy of the printed Prospectus, free of charge, upon request during normal business hours from 9:00 a.m. on Tuesday, September 5, 2017 until 12:00 noon on Friday, September 8, 2017 at the following locations:

1. any of the following branches of the receiving bank for the Hong Kong Public Offering:

Standard Chartered Bank (Hong Kong) Limited

	<u>Branch Name</u>	<u>Address</u>
Hong Kong Island	88 Des Voeux Road Branch	88 Des Voeux Road Central, Central
Kowloon	Mongkok Branch	Shop B, G/F, 1/F & 2/F, 617-623 Nathan Road, Mongkok
New Territories	Tsuen Wan Branch	Shop C, G/F & 1/F, Jade Plaza, 298 Sha Tsui Road, Tsuen Wan

2. any of the following offices of the Hong Kong Underwriters:

(a) **China International Capital Corporation Hong Kong Securities Limited**, at 29th Floor, One International Finance Centre, 1 Harbour View Street, Central, Hong Kong;

(b) **Jefferies Hong Kong Limited**, at Suite 2201, 22/F, Cheung Kong Center, 2 Queen’s Road Central, Central, Hong Kong;

(c) **Fosun Hani Securities Limited**, at Suite 2101-2105, 21/F, Champion Tower, 3 Garden Road, Central, Hong Kong;

(d) **Haitong International Securities Company Limited**, 22/F, Li Po Chun Chambers, 189 Des Voeux Road Central, Hong Kong;

(e) **Huatai Financial Holdings (Hong Kong) Limited**, Room 5801-05 & 08-12, 58/F, The Center, 99 Queen’s Road Central, Hong Kong.

3. the Depository Counter of HKSCC at 1/F, One & Two Exchange Square, 8 Connaught Place, Central, Hong Kong.

Details of where printed Prospectuses may be obtained will be displayed prominently at every designated branch of Standard Chartered Bank (Hong Kong) Limited where WHITE Application Forms are distributed:

Standard Chartered Bank (Hong Kong) Limited

	<u>Branch Name</u>	<u>Address</u>
Hong Kong Island	88 Des Voeux Road Branch	88 Des Voeux Road Central, Central
	Hennessy Road Branch	399 Hennessy Road, Wanchai
	North Point Centre Branch	Shop G, G/F, North Point Centre, 284 King's Road, North Point
Kowloon	Mongkok Branch	Shop B, G/F, 1/F & 2/F, 617-623 Nathan Road, Mongkok
	Telford Gardens Branch	Shop P9-12, Telford Centre, Telford Gardens, Tai Yip Street, Kwun Tong
New Territories	Tsuen Wan Branch	Shop C, G/F & 1/F, Jade Plaza, 298 Sha Tsui Road, Tsuen Wan
	Tseung Kwan O Branch	Shop G37-40, G/F, Hau Tak Shopping Centre East Wing, Hau Tak Estate, Tseung Kwan O

During normal business hours from 9:00 a.m. on Tuesday, September 5, 2017 until 12:00 noon on Friday, September 8, 2017, at least three copies of the printed Prospectus will be available for inspection at every location where the **WHITE** and **YELLOW** Application Forms are distributed as set out in “*How to Apply for Hong Kong Offer Shares and Reserved Shares*” in the Prospectus.

In this announcement, unless the context otherwise requires, the following terms shall have the meanings set out below:

- “Application Form(s)”** WHITE Application Form(s), YELLOW Application Form(s) and GREEN Application Form(s), or where the context so requires, any of them, relating to the Hong Kong Public Offering and BLUE Application Form(s) relating to the Preferential Offering
- “Assured Entitlement”** the entitlement of the Qualifying Fosun International Shareholders to apply for the Reserved Shares on an assured basis pursuant to the Preferential Offering determined on the basis of their respective shareholdings in Fosun International on the Record Date
- “Company”** Sisram Medical Ltd, a company incorporated in Israel with limited liability on April 25, 2013
- “Capitalization Issue”** the issue of new Shares to Magnificent View Investments Limited, Ample Up Limited (能悅有限公司) and Chindex Medical Limited (美中互利醫療有限公司) on a *pro rata* basis immediately prior to completion of the Global Offering by way of the capitalization of part of the share premium of the Company and by way of the capitalization of the Capital Notes (as defined in the Prospectus) issued by the Company, as further described in “History and Corporate Structure” of the Prospectus
- “Director(s)”** the director(s) of the Company or any one of them
- “Fosun International”** Fosun International Limited (復星國際有限公司), a company incorporated in Hong Kong with limited liability, the shares of which are listed on the Main Board of the Stock Exchange, and a controlling shareholder of the Company
- “Global Offering”** the Hong Kong Public Offering and the International Offering (including the Preferential Offering)
- “HKSCC”** Hong Kong Securities Clearing Company Limited, a wholly owned subsidiary of Hong Kong Exchanges and Clearing Limited

“Hong Kong”	the Hong Kong Special Administrative Region of the People’s Republic of China
“Hong Kong Public Offering”	the proposed offering of Shares to the public in Hong Kong for subscription, on and subject to the terms and conditions set out in the Prospectus and the Application Forms
“Hong Kong Underwriters”	the underwriters for the Hong Kong Public Offering as listed in the sub-section headed “Underwriting — Underwriters — Hong Kong Underwriters” in the Prospectus
“International Offering”	the proposed offering of the Shares to institutional, professional, corporate and other investors (other than to retail investors in Hong Kong), as further described in the section headed “Structure of the Global Offering” in the Prospectus
“Listing Committee”	the listing committee of the Stock Exchange
“Preferential Offering”	the preferential offering to the Qualifying Fosun International Shareholders as an Assured Entitlement out of the Shares being offered under the International Offering at the Offer Price, on and subject to the terms and conditions set out in the Prospectus and in the BLUE Application Form, as further described in “ <i>Structure of the Global Offering — The Preferential Offering</i> ” in the Prospectus
“Prospectus”	the prospectus to be issued on September 5, 2017 by the Company
“Qualifying Fosun International Shareholders”	Fosun International Shareholders whose names appeared in the register of members of Fosun International on the Record Date, other than Non-Qualifying Fosun International Shareholders (as defined in the Prospectus)
“Record Date”	August 31, 2017, being the record date for determining the Assured Entitlement of the Qualifying Fosun International Shareholders to the Reserved Shares

“Reserved Shares”	the Shares being offered by the Company to the Qualifying Fosun International Shareholders pursuant to the Preferential Offering as the Assured Entitlement, which are to be allocated out of the Shares being offered under the International Offering
“Shares”	ordinary shares in the share capital of the Company
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“U.S. Securities Act”	the United States Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder
“United States”	the United States of America, its territories, its possessions and all areas subject to its jurisdiction

By order of the Board of Directors
Sisram Medical Ltd
YI LIU
Chairman

Hong Kong, September 4, 2017

As at the date of this announcement, the executive Directors are Mr. Yi LIU and Mr. Lior Moshe DAYAN; the non-executive Directors are Mr. Yifang WU, Mr. Chun LI, Mr. Yao WANG and Ms. Yu HU; the independent non-executive Directors are Mr. Heung Sang Addy FONG, Mr. Chi Fung Leo CHAN, Ms. Jenny CHEN and Mr. Kai Yu Kenneth LIU.